Difference in Mortality After Hip Fracture is Associated with Postdischarge Prescription of Antithrombotic Prophylaxis: A Case-Control Study

Abstract

This study was undertaken to determine whether a prolongation of pharmaceutical antithrombotic prophylaxis beyond hospitalization for hip fracture is associated with a reduced mortality rate. One hundred seventy-nine cases with hip fracture (patients older than 50 years of age) admitted to local general hospitals in 1999 who received postdischarge prescription of any antithrombotic agent (heparin, oral anticoagulants, antiplatelet drugs) and 179 ageand sex-matched patients with hip fracture who did not were included. Postdischarge mortality was assessed at 90 days. Compared with patients who did not receive postdischarge prescription of antithrombotic agents, those who did had an odds ratio of 0.22 (95% confidence interval 0.08-0.59) for all causes of mortality. This result did not change after excluding nonvascular mortality (odds ratio, 0.17; confidence interval, 0.03-0.73; p=0.011). Patients admitted to the hospital for hip fracture are at high risk of death after discharge if they are not given antithrombotic treatment. To substantiate these data, ad hoc prospective randomized trials are needed.

Keywords

Antithrombotic prophylaxis Hip fracture

References

1. Saisbury R . Hip fracture. Rev Clin Gerontol 1991;1:67-67.

2. Perez JV , Warwick DJ , Case CP , et al. Death after proximal femoral fracture: An autopsy study. Injury 1995;26:237-237.

3. Pellegrini VD , Clement D , Lush-Emhann C , et al. Natural history of thromboembolic disease after total hip arthroplasty. Clin Orthop 1996;333:27-27.

4. Lotke PA , Steimberg ME , Ecker ML . Significance of deep venous thrombosis in the lower extremity after total joint arthroplasty. Clin Orthop 1994;299:25-25.

5. Geerts WH , Heit JA , Clagett CP , et al. Prevention of venous thromboembolism. Chest 2001;119:132S-132S.

6. Todd CD , Freeman CJ , Camilleri-Ferrante C , et al. Differences in mortality after fracture of hip: The East Anglian audit. BMJ 1995;310:904-904.

7. Raine GET . A comparison of internal fixation and prosthetic replacement for recent displaced subcapital fractures of the neck of the femur. Injury 1973;5:25-25.

8. Hunter GA . A comparison of the use of internal fixation and prosthetic replacement for fresh fractures of the neck of the femur. Br J Surg 1969;56:229-229.

9. Schurch MA , Rizzoli R , Mermillod B , et al. A prospective study on the socioeconomic aspects of fracture of the proximal femur. J Bone Miner Res 1996;11:1935-1935.

10.

10. Bergqvist D , Benoni G , Bjorgell O , et al. Low molecular weight heparin (enoxaparin) as prophylaxis against VTE after total hip replacement. N Engl J Med 1996;335:696-696.

11.

11. Lassen MR , Borris LC , Andersson BS , et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty: The Danish prolonged prophylaxis (DaPP) study. Thromb Res 1998;89:281-281.

12.

12. Dahl OE , Andreassen G , Aspelin T , et al. Prolonged thromboprophylaxis following hip replacement surgery-results of a double-blind, prospective, randomized, placebo-controlled study with dalteparin (Fragmin). Thromb Haemost 1997;77:26-26.

13.

13. Planes A , Vochelle N , Darmon J-Y , et al. Risk of deep venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo. Lancet 1996;348:224-224.

14.

14. Hull RD , Pineo GF , Francis CW , et al. Low molecular weight prophylaxis using dalteparin extended out-of-hospital warfarin versus out-of-hospital placebo in hip arthroplasty patients. A double-blind randomized comparison. Arch Intern Med 2000;160:2208-2208.